Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
23.41
-0.15 (-0.64%)
At close: Sep 16, 2025, 4:00 PM EDT
23.62
+0.21 (0.91%)
After-hours: Sep 16, 2025, 7:48 PM EDT
Janux Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts that cover Janux Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $79.5, which forecasts a 239.60% increase in the stock price over the next year. The lowest target is $41 and the highest is $200.
Price Target: $79.5 (+239.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Janux Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 3 | 3 | 5 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 8 | 8 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Initiates $100 | Strong Buy | Initiates | $100 | +327.17% | Sep 10, 2025 |
| Stifel | Stifel | Strong Buy Initiates $45 | Strong Buy | Initiates | $45 | +92.23% | Sep 10, 2025 |
| Guggenheim | Guggenheim | Strong Buy Initiates $72 | Strong Buy | Initiates | $72 | +207.56% | Sep 4, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $42 | Buy | Initiates | $42 | +79.41% | Aug 19, 2025 |
| Raymond James | Raymond James | Buy Initiates $65 | Buy | Initiates | $65 | +177.66% | Jul 11, 2025 |
Financial Forecast
Revenue This Year
2.35M
from 10.59M
Decreased by -77.77%
Revenue Next Year
5.43M
from 2.35M
Increased by 130.50%
EPS This Year
-2.35
from -1.28
EPS Next Year
-3.01
from -2.35
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.5M | 63.2M | |||
| Avg | 2.4M | 5.4M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.8% | 2,583.4% | |||
| Avg | -77.8% | 130.5% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.07 | -1.96 | |||
| Avg | -2.35 | -3.01 | |||
| Low | -3.21 | -4.66 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.